🔗 Share this article Social Media Content Creators Fueling Unofficial Trade for Unlicensed Slimming Drug A shadow economy for unapproved slimming medications is being driven by TikTok fitness influencers and sellers on communication apps, according to new investigations. Investigational Drug Acquiring Popularity Online The experimental drug, which remains in clinical trials, is being advertised by online personalities for its supposed weight-reducing properties. Followers are urged to message these accounts privately for supplier links, while also obtaining discount codes. Active Commerce on Messaging Platforms Additionally, a robust trade exists on Telegram, where groups with numerous of participants share “before and after” photos, injection guides and claims of rapid British shipping. Vendors promote the substance there before directing customers to other platforms for transactions. Learning About Retatrutide This medication is an investigational injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could help patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted digitally as the next Ozempic. Medical Experts Voice Concerns However, doctors and pharmacists have cautions that the sale of what remains an unapproved drug in the United Kingdom is a cause for concern and could result in individuals injecting products of unknown origin. Some experts stated the demand for the experimental drug could be linked to the rising cost of approved weight loss products such as Mounjaro. Regulatory Status and Enforcement Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012. Some influencers try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still breach medicines, marketing, and customer regulations, risking penalties, legal action or imprisonment. Platform Reaction and Material Elimination Based on the social media company, the service has removed problematic content and banned associated hashtags and search suggestions. The organization said it was committed to maintaining the platform secure and investing in strengthening compliance measures. Digital Marketplace Operations Investigations also discovered communities with up to 9,000 members marketing retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays groups with numerous of users, populated with images of slimming results, positive testimonials and detailed guides for mixing or administering at residence. Within minutes of joining one group, a vendor posted contact information, where most purchases take place. The vendor sent an instruction manual and guaranteed shipping within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. None inquired about weight, medical conditions or past usage. Item Information and Costs Within these communities, messages display black plastic packages with Royal Mail stickers, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.” Customers can select between dry substance containers, mixed at residence with sterile water, or pre-filled injectors usually priced at £160 for 20mg. When asked how long a injector should last, vendors give contradictory answers ranging from a several days to “depends on your body”. Platform Oversight and Safety Measures A spokesperson for the messaging service said it actively moderated harmful material on its service including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”. Medical Professional Warnings “Individuals are injecting substances they can’t verify. Although the research behind this drug is sound, these digital products may not contain what they claim,” said Jason Murphy, the head of pharmaceutical services at Chemist4U. Dr Crystal Wyllie of an online medical service linked the surge in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to online platforms. But counterfeit injections are highly risky. You cannot know what’s contained or whether the conditions they were made in was sterile,” she said. Her staff has previously encountered individuals injured by personal administration from unverified sources. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These materials could be contaminated or incorrectly dosed.” Manufacturer Statement A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this point no one can market [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company investigational substance not yet approved … may expose users to potentially serious medical dangers”.